ArticleClinical epigenetics2026
Preliminary study on PAX1/JAM3 methylation and HPV viral load in CIN3-like squamous cell carcinoma: Are there differences from CIN3 and early invasive carcinoma?
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveCervical intraepithelial neoplasia grade 3 (CIN 3)-like squamous cell carcinoma (SCC) is a recently identified subtype of cervical cancer with a deceptive growth pattern. It mimics the phenotype of CIN 3, involving endocervical crypts, presenting significant challenges and potential for diagnostic confusion. This study aims to clarify the differences in epigenetic profiles and HPV viral load(VL) among CIN 3, CIN 3-like SCC, early invasive SCC, and invasive SCC.
methodsA retrospective analysis was conducted on 138 cases of cervical high-grade lesions and SCC diagnosed at Peking University People's Hospital from March 2022 to June 2024. The cases included 65 high-grade squamous intraepithelial lesions (HSIL) [23 CIN 2 and 42 CIN 3] and 73 SCC [27 CIN 3-like SCC, 21 early invasive SCC, and 25 invasive SCC]. Histological samples were analyzed for methylation levels of the epigenetic factors PAX1 and JAM3, as well as HPV VL.
resultsMethylation levels of PAX1 and JAM3, as well as total HPV VL, were significantly higher in cervical cancer than in HSIL(< 0.001). The PAX1 methylation level of CIN3 was significantly lower than that of invasive SCC, but there was no significant difference compared with CIN3 and CIN 3-like SCC; For the PAX1/JAM3 methylation levels in CIN 3-like SCC, no statistically significant differences were observed when compared with those in early invasive SCC and invasive SCC. The HPV VL in CIN 3-like SCC was significantly higher than that in CIN 3 and early invasive SCC, but no significant difference was found compared with invasive SCC. In the same stage of FIGO, although PAX1/JAM3 methylation and HPV VL (especially HPV16/18 VL) showed a tendency to increase in CIN3-like SCC compared with early invasive SCC, the difference was not significant, further expansion of sample size is needed to confirm this.
conclusionPAX1 and JAM3 methylation levels are significantly higher in SCC than HSIL, but no difference in methylation levels was observed between CIN 3-like SCC, early invasive SCC, and invasive SCC. Total HPV VL (especially HPV16/18 VL) in CIN3-like SCC is significantly higher than that in CIN3 and early invasive SCC, suggesting potential shared and distinct features in epigenetics and HPV VL between CIN3-like SCC and early invasive SCC, which need more molecular biology research to explore the difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.